At current trading levels, CareRx looks like a good pickup, said Echelon Capital Markets analyst Stefan Quenneville in a Thursday report where he kept a Buy rating on the stock.
Ahead of what he sees as a slow margin recovery in 2023, Desjardins Securities analyst Gary Ho has lowered his price target on CareRX. In a research update to…